Maze Therapeutics, Inc.

Maze Therapeutics, Inc.

MAZE - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.88B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Maze Therapeutics, Inc.Maze Therapeutics, Inc.-12--35%-0.1
$75.00

Target Price by Analysts

139.1% upsideMaze Therapeutics Target Price DetailsTarget Price
$3.86

Current Fair Value

87.7% downside

Overvalued by 87.7% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.88 Billion
Enterprise Value$1.78 Billion
Earnings per Share$-3.05
Beta2.03
Outstanding Shares60,864,851

Return

Return on Equity-35.35%ROE
Return on Assets-29.61%
Return on Invested Capital-30.77%

Valuation & Multiples

P/E Ratio-11.96P/E Ratio
PEG-20.13PEG
Price to Sales-Price to Sales
Price to Book Ratio4.48Price to Book Ratio
Enterprise Value to Revenue89.14
Enterprise Value to EBIT-11.99
Enterprise Value to Net Income-12
Total Debt to Enterprise0.03
Debt to Equity0.14Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 9, 2026
EPS
-$0.79
Est. -$0.76
Revenue Estimate
$333,333
Consensus analyst estimate

Next Earnings Call

Expected Date
March 24, 2027
EPS Estimate
-$0.84
Consensus analyst estimate
Revenue Estimate
$333,333
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.49, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.4870▼ 47.49%
Total Calls180,300▲ 174.85%
Total Puts87,800▲ 39.14%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %102.31%▲ 2.65%
Total Invested$1.64B▼ 6.43%
Investors Holding164▼ 5.00%

About Maze Therapeutics, Inc.

141 employees
CEO: Jason Coloma

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small mol...

Maze Therapeutics Insider Information FAQ

Stockcircle shows 30 open-market insider sales for Maze Therapeutics in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.

Questions & Answers